Clinical trials: Efavirenz
Drug Effects
Efavirenz and Ritonavir on Human Brain P-Glycoprotein
To determine the effects of ritonavir and efavirenz on the activity of P-glycoprotein in human brain.
- Trial name
- NCT01668147
- Testing
- [11C] desmethyl-loperamide, Control - no pretreatment, Oral ritonavir
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HIV Disease
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
In this study we will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the brain…
- Trial name
- NCT01929759
- Testing
- Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Cardiovascular Disease
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.
- Trial name
- NCT01585038
- Testing
- Efavirenz, Rilpivirine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV Infections, Tuberculosis
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
The purpose of this pharmacokinetic (PK) study was to evaluate if a double dose (3 mg) of levonorgestrel (LNG) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin…
- Trial name
- NCT03819114
- Testing
- Levonorgestrel (LNG)
- Where
- 18 sites in United States, Botswana and 5 more
- Volunteers
- 122 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV/AIDS, Contraception
Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
This study will evaluate the frequency of ovulation and cervical mucus quality of HIV-infected Ugandan women on efavirenz-based antiretroviral therapy using either a single etonogestrel implant or two etonogestrel implants for at…
- Trial name
- NCT03282799
- Testing
- etonogestrel implant
- Where
- Uganda
- Volunteers
- 72 people
- Sponsor
- Catherine Anne Chappell
HIV Infections, HIV-1
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen…
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Trial name
- NCT00540449
- Testing
- TMC278, Efavirenz
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 694 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside…
- Trial name
- NCT02345226
- Testing
- FTC/RPV/TAF, EFV/FTC/TDF
- Where
- 117 sites in United States, Belgium and 7 more
- Volunteers
- 881 people
- Sponsor
- Gilead Sciences
Healthy
The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers
The primary objective of this study is to determine the average bioequivalence of tenofovir, emtricitabine and efavirenz in an extemporaneously prepared oral liquid formulation (test formulation) compared with the commercially…
- Trial name
- NCT00862823
- Testing
- tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Human Immunodeficiency Virus Type 1
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
- Trial name
- NCT00110305
- Testing
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 368 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
CCTG 589 is a randomized, open-label, pilot study comparing the efficacy, safety and tolerability of RAL plus LPV/r to EFV plus TDF/FTC in HIV-infected, treatment-naïve subjects.
- Trial name
- NCT00752856
- Testing
- Kaletra + Isentress, Atripla
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of California, San Diego
HIV Infection
Atripla to Raltegravir Switch Study for CNS Toxicity
The purpose of the study is to investigate the benefits of switching away from efavirenz (part of the combination pill, Atripla®) in patients with central nervous system side effects (such as insomnia {difficulty with sleeping}…
- Trial name
- SSAT036 (NCT01195467)
- Testing
- Truvada/Raltegravir
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- St Stephens Aids Trust
Healthy Participants
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
This is a Phase 1, open-label, multiple dose, single fixed-sequence, 2-period study to evaluate the effect of abrocitinib on the pharmacokinetics (PK) of caffeine, efavirenz and omeprazole in healthy adult participants.
- Trial name
- NCT05067439
- Testing
- Abrocitinib, Omeprazole, Caffeine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV, HIV-associated Neurocognitive Disorder
Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
In this study investigators will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the…
- Conditions
- HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
- Trial name
- NCT01978743
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Uncomplicated Plasmodium Falciparum Malaria
Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
This project determines the pharmacokinetic/pharmacodynamic (PK/PD) of an extended artemether-lumefantrine (AL) dosing regimen in HIV-infected children on efavirenz (EFV)-based antiretroviral therapy (ART) that is designed to…
- Trial name
- EXALT (NCT03453840)
- Testing
- Artemether-lumefantrine
- Where
- 2 sites in Uganda
- Volunteers
- 305 people
- Sponsor
- University of California, San Francisco
Pharmacokinetics, Drug Interactions
Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2
The purpose of this study is to evaluate the effects of a chronic co-medication of efavirenz on pharmacokinetics and sterol-lowering effects of ezetimibe at steady-state in healthy subjects genotyped for ABCB1, ABCC2, CYP2B6 and…
- Conditions
- Pharmacokinetics, Drug Interactions, Pharmacodynamics, Intestinal Transporter Expression
- Trial name
- NCT00810303
- Testing
- Ezetrol (ezetimibe) multiple dose, Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose, Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
HIV Infections
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1.
- Trial name
- NCT00350272
- Testing
- Elvucitabine, Lamivudine, Tenofovir
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Drug Interaction
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
This study evaluates whether there is an interaction between etonogestrel, the progestin hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication used to treat HIV.
- Trial name
- NCT01980342
- Testing
- Efavirenz
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV-1
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with…
- Trial name
- NCT00824421
- Testing
- UK-453, 061, EFV +TVA
- Where
- 31 sites in Argentina, Australia and 7 more
- Volunteers
- 195 people
- Sponsor
- Pfizer
Efavirenz, Metabolism and Pharmacokinetics Changes
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.
- Trial name
- NCT01104376
- Testing
- Efavirenz, voriconazole
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Indiana University